HSP-glomerulonephritis Trial: MP vs CyA

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2011

Conditions
Purpura, Schoenlein-Henoch
Interventions
DRUG

Methylprednisolone pulses plus prednisone versus Cyclosporine A

The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.

Trial Locations (1)

90029 OYS

Dept. of Pediatrics, Oulu University Hospital, Oulu

All Listed Sponsors
lead

Oulu University Hospital

OTHER

NCT00425724 - HSP-glomerulonephritis Trial: MP vs CyA | Biotech Hunter | Biotech Hunter